Form 4 for INVA Innoviva, Inc.

Accepted 2024-01-22 00:00:00 ET · period of report 2024-01-18 · accession 0000899140-24-000058 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-01-22	2024-01-18	INVA	Ronsheim Matthew	See Remarks	F - Tax	$16.05	-1,600	28.8K	-5%	-$25.7K
D	2024-01-22	2024-01-18	INVA	Ronsheim Matthew	See Remarks	A - Grant	$0.00	+60.0K	93.1K	+181%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-01-18	F	D	1,600	$16.05	28,817	D	—	—	(F1) The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
2	Derivative	Nonqualified Stock Option	2024-01-18	A	A	60,000	$0.00	93,100	D	$16.05 · 2025-02-20 to 2034-01-17	60,000 Common Stock	(F2) 25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims.